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Background: When the publication of important trial data is delayed, or data are never published, this will prevent the proper practice of evidence based
medicine through robust systematic reviews. Clinical trial registries allow researchers to interrogate the trial protocol and afford the opportunity to
identify studies that have been completed and so determine the time lag between completion and publication.
Methods:We searched ClinicalTrials.gov with the keywords ‘cystic fibrosis’. Intervention trials which had completed 1st Jan 1998–31st Dec 2010
were selected. Time to publication in a peer-reviewed journal was calculated. Survival analyses using the log rank test were undertaken.
Results:We identified 142 records. Of these, 62 had full paper publications. The median time to publication was 3.25 years. Phase of study (phase
one studies more delayed, p=0.024) but not source of funding (p=0.34) was associated with time to publication.
Conclusions: Clinical trials in cystic fibrosis take a considerable amount of time to report their findings. More importantly, a large number of trials
fail to report at all.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. Open access under CC BY license.Keywords: Cystic fibrosis; Publication bias; Clinical trials1. Introduction
Evidence based medicine depends upon access to the results of
well designed trials which have minimal bias [2]. To fully
understand the effect of an intervention, one should consider all the
available evidence. Without this, conclusions drawn from the
literature, upon which clinical decisions rest, may be erroneous.
Unfortunately, not all trial results are published. Failure to publish
data in a peer-reviewed journal can occur for several reasons,
including editorial decisions, difficulties in publishing “negative
results” or because the investigator or sponsor has not submitted the
results. Thus all the relevant trial data are often not available to
clinicians, systematic reviewers, health policy decision makers and
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OUntil recently, the number of unpublished trials was unknown,
as therewere no registries of conducted trials. However, in 2005 the
International Committee ofMedical Journal Editors announced that
trial publication in participating journals would be dependent upon
registration of a summary protocol of the trial with a public registry
[3]. This allows an assessment to be made of the total number of
clinical trials in any particular field, and additionally allows
comparison of the trial report with a protocol summary. Given that
registry entries give a completion date of each trial, registries allow
the calculation of the time taken from completion of a clinical trial
to publication in a peer-reviewed journal.
There is bias in the medical literature, and this can have an
impact on the findings of systematic reviews [4]. Time-lag bias
has been documented in other areas of clinical practice, such asne 2011 [1].
es, University of Nottingham, E Floor East Block, Queens Medical Centre,
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Table 1
Characteristics of included studies.
Characteristic Subgroup n (%)
Age range
Adult 38 (26.6%)
Adult and paediatric 69 (48.4%)
Paediatric 21 (14.8%)
Missing data 14 (10.2%)
Funding source
Industry 68 (47.9%)
Mixed 27 (19.0%)
NIH or US Gov 7 (4.9%)
Other 40 (28.2%)
Phase of study
I 26 (18.3%)
II 46 (32.4%)
III 34 (23.9%)
IV 9 (6.3%)
Unclassified 27 (19.1%)
Number of centres
Multi-centre 60 (42.3%)
Single centre 62 (43.7%)
Missing data 20 (14.1%)
Number of nations
Multinational 121 (85.2%)
Single nation 21 (14.8%)
No. of study participants
Median 30
Interquartile range 18–74
Range 3–517
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positive results are published more quickly than other studies
[6]. Although it is the most common inherited life limiting
disease in the Caucasian population, cystic fibrosis (CF) is a rare
disease. Thus the total CF trial literature can be assessed. We
present an evaluation of time taken to report clinical trials which
involved patients with CF.
2. Methods
We searched ClinicalTrials.gov (search date 10th Jan 2011)
with the key words ‘cystic fibrosis’, and selected the subgroup of
intervention trials which had a recorded completion date between
1st Jan 1998 and 31st Dec 2010. The output from a ClinicalTrials.
gov search can be downloaded in a spreadsheet format, which
formed the basis for the subsequent analysis. Using details from
the registry record of each trial (trial ID, sponsor, trial name and
trial investigators) we searched online (using PubMed, Google
Scholar and the Cochrane Central Register of Clinical Trials) for
the first publication relating to that trial.
Where we could not identify a publication in a peer-reviewed
journal, we contacted the listed investigator in the Clinical-
Trials.gov record, to determine if the trial had been published.
Investigators were not always listed in the record, in which case
we contacted the study sponsor.
We categorised each trial by the funding source (Industry,
Mixed e.g. Industry/Charity collaboration, National Institutes of
Health/U.S. Government, or “other”); phase of study; geo-
graphic location of study (single centre vs. multi-centre and
national vs. international study). A script was written which
automated the extraction of these data from ClinicalTrials.gov
for each trial in the dataset. Number of centres and countries in a
study are not part of the standard downloaded spreadsheet and
so we could not analyse this variable.
The primary endpoint for our analysis was the time to first
publication of a trial report in a peer-reviewed journal from
completion of the study. We used the ‘primary completion date’
(recorded on ClinicaTrials.gov) as the time when the study
completed. Where this field was not completed we used the
‘completion date’. Where both fields were missing the trial was
excluded from the analysis. We conducted a survival analysis
for the whole cohort of studies, and additionally several
subgroup analyses using the log rank test to determine if the
categorical variables funding source, phase of study, number of
countries, age of participants and number of sites were
associated with the likelihood of publication. We used a Cox
proportional hazard model to investigate the effects of the
enrolment size upon time to publication. We took statistically
significant results from these univariate analyses and combined
into a Cox proportional hazards multivariate model to confirm
that they remained predictors of time to publication.
Statistical analysis was undertaken with R version 2.13.1 [7].
3. Results
We identified 142 study records on ClinicalTrials.gov which
met the inclusion criteria. The search of online databases foundthat 59 of these had publications in a peer-reviewed journal. We
contacted the investigators for the remaining studies, and
received 29 responses. This identified a further 3 studies which
had been published. We did not count 13 studies which had
been published in abstract form only. A summary of the
included trial characteristics is shown in Table 1.
Overall, 62 (43.7%) completed studies have published in a
peer-reviewed journal. However this value considers all studies
equally, irrespective of time since study completion. For
example, for ten unpublished studies there was less than
365 days of follow up, so the overall rate of 43.7% publication
underestimates actual publication. We conducted a survival
analysis, using the endpoint of publication in a peer-reviewed
journal, and calculated cumulative publication percentage over
a 5-year period for all studies, right censoring studies which had
not published at the time of the search (Fig. 1). Records of the
completion date or primary completion date were missing for 10
studies, which were excluded from the analysis. The median
time to publication of all studies was 3.25 years. As can be seen
in Fig. 1, a large proportion failed to publish within 5 years.
We conducted survival analyses (log rank test) with the
studies grouped by funding source and study phase, (e.g. I, II,
III, or IV) (see Fig. 2A and B and Table 2). We found no
evidence that the funding source influences the time to
publication (p=0.34; median times to publication were:
Industry 3.25 years, Mixed 3.92 years, NIH or US Gov
9.92 years, Other 2.67 years, see also Table 2). Analysis of
time to publication grouped by phase of study suggested that
study phase influences timing of publication (p=0.024; median
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Fig. 1. Survival graph showing time to publication (in a peer-reviewed journal)
of all studies within the dataset. Vertical bars indicate right censored studies
(those which had not published at the end of the study period on the 11th Jan
2011 when the ClinicalTrials.gov search took place).
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Fig. 2. A. Survival graph showing time to publication of studies, categorised
according to funding body listed on ClinicalTrials.gov. There were only 5
included studies in the “NIH or US Gov” group. There was no significant
difference between groups in the proportion of studies which published within
the follow up period. B. Survival graph showing time to publication of studies
grouped by study Phase. Phase I studies were least likely to publish results.
Vertical bars on each plot indicate right censored studies.
Table 2
Percentage Publication Rate by Funding Source. Publication rates for the first
5 years following completion. Percentages refer to cumulative proportion of
studies published by year for each group. n, numbers represent studies for which
the time to publication data were available. For 10 studies these data were not
available. The total numbers in each category were as follows: Industry=68,
Mixed=27, NIH or US Gov=7, Other=40.
Year Industry
(n=65)
Mixed
(n=22)
NIH or US Gov
(n=5)
Other
(n=40)
1 1.7 4.8 40 12.7
2 19.3 20.4 40 30.4
3 44.9 46.9 40 51.9
4 60.5 53.6 40 64.4
5 60.5 60.2 40 64.4
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Phase II 2.84 years, Phase III 3.08 years, Phase IV 2.17 years).
Examination of the survival graphs suggests that Phase I studies
take longer and are less likely to publish compared to the later
phase studies (Fig. 2B). We found no evidence that international
studies are more likely to publish compared to single nation
studies (log rank p=0.20), no evidence that multi-site trials are
more likely to publish compared to single centre studies (log rank
p=0.99; data on number of sites were not available for 20 studies
which were excluded from this analysis), and no evidence that
age-group of participants influenced likelihood of publication
(log rank p=0.95). In a univariate Cox proportional hazard
analysis, studies with a larger number of participants enrolled
were more likely to publish more quickly (p=0.00565). This
enrolment was no longer significant (p=0.0510) in the
multivariate model including study phase (the other significant
variable identified in the univariate analysis).
4. Discussion
We have found that on average it takes 3.25 years between
completion of a clinical trial in cystic fibrosis and the
publication of the trial report in a peer-reviewed journal.
Importantly a large proportion of studies fail to report within
5 years of study completion. We have also found evidence that
Phase I studies are less likely to report.
It was surprisingly difficult in some cases to match clinical
trial reports with the record on ClinicalTrials.gov. Often the title
of the study is different, and the lead investigator is not always
an author on the final peer-reviewed trial report. Although some
trial reports give the trial ID number in the abstract or as a
footnote to the paper, this is not universal.
In a recent systematic review of studies of time to publication
of clinical trial results, the two included studies investigated
either the time of granting of ethical approval for the study or
the time of first patient enrolment [6]. In this systematic review,
studies with positive results were reported within 4–6 years,
17M.N. Hurley et al. / Journal of Cystic Fibrosis 11 (2012) 14–17and negative results within 6–8 years. In our study, the median
time for publication was 3.25 years, however this did not
include the time taken to actually conduct the trial. We reasoned
that some trials may require a longer period of follow up, or may
take longer to recruit patients with a rare disease, so we
preferred to measure the time to publication in terms of the
interval after the study had completed.
We made great efforts to try to ensure that we have found all
clinical trial reports, published in a peer-reviewed journal. In
addition to using 3 search engines to locate trial reports, we also
contacted either the lead investigator or (where there was no
record of the investigator) the sponsor of the study. We believe
that we have found all the published studies. We present the
data through a survival analysis, which also allowed robust
statistical comparison between specific subgroups.
We did not use registries other than ClinicalTrials.gov (such
as the ISRCTN or the WHO trial registry). Neither EudraCT nor
ISRCTN includes a completion date. Recent additions to
ClinicalTrials.gov such as the facility to upload summary study
results will also make ClinicalTrials.gov a valuable resource for
research into publication bias in the future [8].
We are reliant upon the study investigators and sponsors for
maintaining accurate records on ClinicalTrials.gov. For exam-
ple, if a trial completed early or late, and the ClinicalTrials.gov
record was not updated, this would introduce error into our
calculated time to publication. We have no way of knowing if a
trial actually completed on the date listed on the trial record.
The response rate after contacting study investigators and
sponsors was low. We received 29 responses which lead to us
identifying a further 3 studies which our initial search had not
located. Although a large proportion of individuals and
institutions who were contacted did not respond, in our opinion
investigators who have published their work are likely to reply
with the details of the publications. We hope therefore to have
found all the relevant publications which fall within our
inclusion criteria.
When patients enter into clinical trials, they do so with the
altruistic expectation that this will help others (and perhaps
themselves) in the future. Dissemination of the data from the
trial in a peer-reviewed clinical trial report which complies with
CONSORT guidelines represents the 'gold-standard' in report-
ing data from clinical trials, and gives the best chance of
carefully considering the data which the trial has generated.
This is essential to making evidence based decisions. We
acknowledge that the complexity of many clinical trials meansthat it can take some time from trial completion to the
submission of the clinical trial report.
We have found that studies take a considerable amount of
time to report. More importantly, a large number of studies fail
to report at all. Delaying publication (or failing to publish) at
best results in delaying the adoption of an improvement in
practice, and at worst results in inadvertently replicating clinical
research or skewing the evidence base such that the wrong
conclusions are made. In our opinion the patients who
contribute time, effort (and expose themselves to a degree of
risk) by taking part in clinical trials deserve to know that the
results of the trials, in which they take part, will be published.
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